the more extreme cases. Published reports of LSD have been small single centre series. We therefore sought to collect a large series of LSD cases from multiple centres to compare to the cases reported in the MAUDE database. Methods: Two experienced interventional cardiologists analysed angiographic images and case histories of 59 LSD cases from 6 high volume European Centres (multicentre case series MCCS). These cases were compared to the 105 individual reports of cases identified from the MAUDE database (MAUDE series). The analysis included mechanism and location of LSD, stent type, and clinical outcome. Mechanism of LSD was divided into guide catheter induced LSD, and secondary device induced LSD. Results: In both series, LSD occurred infrequently with circumflex interventions (7%), 2.25mm diameter stents (6%) and < 10mm length stents (3%). Lesion calcification (35% cases) and tortuosity (30% cases) were common. LSD occurred at the proximal edge alone in >80% cases. Guide catheter induced LSD was less common in the MAUDE series (17%) than the MCCS (62%, p<0.001). Element-type stents were involved in guide catheter induced LSD in 75% cases and secondary device LSD in 82% cases. Major complications occurred more frequently in the MAUDE series (13%) than the MCCS (2%, p¼0.04), and were more frequent (33% MCCS, 67% MAUDE) if the LSD was untreated than if re-ballooning/stenting was performed (0% MCCS, 6% MAUDE; p<0.0001). Conclusions: LSD usually occurred at the proximal end of the stent, was associated with complex disease and occurred infrequently with small stents and circumflex interventions. The Element-type platform was the commonest stent involved in both guide catheter and secondary device LSD. In the MAUDE series guide catheter LSD was under-represented and cases involving major complications were over-represented. Major complications including stent thrombosis, emergency CABG and death were much commoner if the stent was not / could not be re-expanded.
Background: There are limited data on treatment and long-term clinical outcome after definitive (angiographically confirmed) stent thrombosis (ST). Methods: Retrospective analysis of baseline characteristics and procedural and clinical outcomes in patients with angiographically confirmed ST (ARC classification) from a cohort of 8069 consecutive unselected patients treated by PCI in a single centre (June 2000 -December 2012 . Results: One hundred thirty consecutive patients with definite ST were included in the analysis (1.6%). a) Main baseline characteristics: male sex 82.3%; age 63AE13; diabetes 38.5%; previous renal failure 23.1%; previous AMI 69.2%, peripheral arterial disease (PAD) 16.6%. Clinical presentation was ST-segment elevation myocardial infarction in 68% and cardiogenic shock in 13%. Mean time from stent implantation to ST was 636AE1168 days. According to ARC classification, 14.6% were acute; 35.4% subacute; 14.6% late and 35.4% very late. Previous implanted stent was DES in 39.2%. b) Main procedural characteristics: IIbIIIa inhibitors were used in 66.2%; IVUS guidance in 44.6%; manual thrombectomy in 70.8%; new stent implantation in 74.6%. c) Main clinical outcomes: in-hospital mortality was 9.2% and one-year mortality was 12.3%. Two patients (1.5%) experienced recurrent ST on follow-up. Type of previously implanted stent (DES or BMS), time of ST (acute, subacute, late or very late), vessel treated and DES implantation for ST treatment were not related to mortality on follow-up. Independent predictors for one-year mortality were age, PAD, cardiogenic shock on admission and multivessel disease. Conclusions: In a cohort of real-life consecutive patients, PCI for ST was relatively infrequent. Patients presenting with ST had high comorbidity levels. Up to one third of patients had very late ST. Nearly half of the PCI were IVUS-guided. One-year mortality and recurrent ST on follow-up was lower than previously reported; this may be explained by the high rate of IVUS-guided PCI.
TCT-478
Effect of different drug-eluting stent design on in-stent restenosis and stent thrombosis platform. There is little clinical data in regard to safety and efficacy outcomes between these two stents after a direct comparison in unselected patients. Our aim was to compare ER-DES with RI-DES stent in regard to occurrence of in-stent restenosis and stent thrombosis in unselected consecutive patients. Methods: Information was obtained from the SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry) for the procedures performed in Västra Götaland County in Western Sweden. The database contains information about all consecutive procedures performed at five PCI centers with approximately 3000 PCI/ year. ER-DES was used from 2008 with complete switch in the whole region to RI-DES in 2011. All procedures performed between 2008-2013 for stable angina, unstable angina, non-STEMI and STEMI were included in the analysis. The two stents were compared using propensity score-adjusted multilevel Cox proportional-hazards regression with stents as primary observation units. The following confounders were included in the calculation of propensity score: age, gender, indication for PCI, smoking habits, hypertension, diabetes, hyperlipidaemia, stent diameter, stent length, stenosis class and procedural success. Results: Between 2008 and 2013, 614 ER-DES and 1858 RI-DES were implanted to 929 patients in 1327 procedures. There were 49 events in total of which 24 cases were in-stent restenosis and 25 cases were stent thrombosis. The use of RI-DES was associated with decreased risk for in-stent restenosis/stent thrombosis at one-year (HR 0.42; 95% CI 0.21 -0.86; P¼0.017). Conclusions: In this registry study RI-DES shows a lower frequency of in-stent restenosis and stent thrombosis compared to ER-DES. Improvement in DES stent design may provide substantial clinical benefit to the patients undergoing PCI. "Real world" registries are an important tool in continuous evaluation of new devices and interventions and for support in decision-making within health-care systems.
TCT-479
Impact Angiograms were reviewed by a core lab for patterns of the 1st and 2nd ISR based on Mehran classification. We examined 1-year death, MI, revasc (TVR and TVF), and major adverse cardiac events (MACE). Results: In 201 patients, 77% had focal and 23% diffuse R-ISR. Focal intrastent (IC) and diffuse intrastent (II) were prevalent patterns of focal and diffuse R-ISR (50% and 42% respectively). Groups were balanced with similar demography and angiography. Within groups original implanted stents were SES (44% vs 56%), PES (32% vs 22%), ZES (0% vs 8.5%), and EES (23% vs 14%) respectively. At 1 year, mortality was higher in diffuse R-ISR patients (9% vs 4.5%, p¼0.06), but MACE was comparable between groups (25% vs 29%, p¼0.59, Figure 1 ). Correlates of revasc were R-ISR within 1-year of the index procedure (HR: 1.8, 95% CI 0.99-3.3, P¼0.05) and female sex (1.62 0.97-2.71, P¼0.06). Conclusions: Resistant ISR is a rare complication of PCI even with newer DES. Though MI, TVR/TVF, and MACE did not differ significantly, those with diffuse R-ISR patterns had 2-fold the mortality rate than those with focal R-ISR. In the DES era, diffuse R-ISR still results in worse clinical outcomes. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM www.jacctctabstracts2013.com B146 JACC Vol 62/18/Suppl B j October 27-November 1, 2013 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
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